Pembrolizumab companion diagnostic - Dako/Merck

Drug Profile

Pembrolizumab companion diagnostic - Dako/Merck

Alternative Names: Lambrolizumab companion diagnostic - Dako/Merck; PD-L1 IHC 22C3 pharmDx

Latest Information Update: 26 Oct 2016

Price : $50

At a glance

  • Originator Dako A/S; Merck & Co
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Non-small cell lung cancer

Most Recent Events

  • 24 Oct 2016 US FDA approves sNDA for pembrolizumab companion diagnostic for Non-small cell lung cancer (Diagnosis, in patients with PD-L1 tumour proportion score of 1% or more)
  • 04 Aug 2016 Launched for Non-small cell lung cancer (Diagnosis) in Europe (unspecified route)
  • 03 Aug 2016 Registered for Non-small cell lung cancer (Diagnosis) in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top